Search clinical trials for: Pembrolizumab

Total 2281 results

Haider Mahdi
Merck Sharp & Dohme LLC; ALX Oncology

Recruiting

Safety and Efficacy of Anti-CD47, ALX148 in Combination With Liposomal Doxorubicin and Pembrolizumab in Recurrent Platinum-resistant Ovarian Cancer

Ovarian Cancer

United States
Tvardi Therapeutics, Incorporated

Recruiting

A Study of TTI-101 as Monotherapy and in Combination in Participants With Locally Advanced or Metastatic, and Unresectable Hepatocellular Carcinoma

Hepatocellular Carcinoma

United States
Fudan University
Merck Sharp & Dohme LLC

Recruiting

Induction of Cisplatin/Nab-paclitaxel/Pembrolizumab Followed by Olaparib/Pembrolizumab Maintenance in mTNBC Patients

Triple Negative Breast Cancer

China
Medicenna Therapeutics, Inc.
Merck Sharp & Dohme LLC

Recruiting

A Beta-only IL-2 ImmunoTherapY Study (ABILITY-1)

Clear Cell Renal Cell Carcinoma | Cervical Cancer | Gastric Cancer | Esophageal Cancer | Ovarian Cancer | Fallopian Tube Cancer | Solid Tumor | Squamous Cell Carcinoma of Head and Neck | Bladder Cancer | Skin Cancer | Triple Negative Breast Cancer | Advanced Solid Tumor | Primary Peritoneal Cancer | Endometrial Carcinoma and other conditions

United States, Australia, Korea, Republic of, Canada
Bryan Schneider, MD
Pfizer; Genentech, Inc.; Indiana University; Foundation Medicine; Vera Bradley Foundation...

Recruiting

Circulating Tumor DNA Enriched, Genomically Directed Post-neoadjuvant Trial for Patients With Residual Triple Negative Breast Cancer (PERSEVERE)

Breast Cancer | Triple Negative Breast Cancer

United States
Sanofi

Recruiting

Study of SAR444881 Administered Alone and in Combination With Other Therapeutics in Participants With Advanced Solid Tumors

Cancer | Neoplasm

United States, Israel
Cardiff University

Recruiting

Phase 1b/II Trial of Pembrolizumab Plus IMRT in Stage III/IV Carcinoma of Anus (CORINTH)

Anal Cancer Stage III A | Anal Cancer Stage III B

United Kingdom, Norway
Icahn School of Medicine at Mount Sinai
Merck Sharp & Dohme LLC; Celldex Therapeutics

Recruiting

Vaccination With Flt3L, Radiation, and Poly-ICLC

Non-Hodgkin's Lymphoma | Metastatic Breast Cancer | Head and Neck Squamous Cell Carcinoma

United States
Hoffmann-La Roche

Active, not recruiting

A Study of Tiragolumab in Combination With Atezolizumab Plus Pemetrexed and Carboplatin/Cisplatin Versus Pembrolizumab Plus Pemetrexed and Carboplatin/Cisplatin in Participants With Previously Untreated Advanced Non-Squamous Non-Small Cell Lung Cancer (SKYSCRAPER-06)

Non-small Cell Lung Cancer (NSCLC)

United States, Korea, Republic of, Canada, Belgium, China, Denmark, Spain, Thailand, United Kingdom, Taiwan, Brazil, Germany, Mexico, Italy, Switzerland, Hong Kong, Japan, France, Turkey, New Zealand, Poland
Amgen

Active, not recruiting

A Study of Bemarituzumab Monotherapy and Combination With Other Anti-cancer Therapy in SqNSCLC With FGFR2b Overexpression (FORTITUDE-201) (FORTITUDE-201)

Squamous-Cell Non-Small-Cell Lung Cancer

France, Belgium, Spain, United States, Taiwan, Korea, Republic of, Japan, Poland
Merck Sharp & Dohme LLC
Eisai Inc.

Active, not recruiting

Efficacy and Safety of Pembrolizumab (MK-3475) With Lenvatinib (E7080/MK-7902) vs. Docetaxel in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC) and Progressive Disease (PD) After Platinum Doublet Chemotherapy and Immunotherapy (MK-7902-008/E7080-G000-316/LEAP-008)

Metastatic Non-Small Cell Lung Cancer

Russian Federation, Australia, United States, Argentina, Canada, Colombia, France, Germany, Greece, Hungary, Israel, Italy, Japan, Korea, Republic of, Portugal, Puerto Rico, Spain, United Kingdom
Belén Retamal-Valdes

Active, not recruiting

Amoxicillin and Metronidazole During or After the Periodontal Treatment

Periodontitis

Brazil
Merck Sharp & Dohme LLC

Completed

Study of Pembrolizumab (MK-3475) in Platinum Pre-treated Recurrent/Metastatic Nasopharyngeal Cancer (MK-3475-122/KEYNOTE-122)

Nasopharyngeal Neoplasms
Hackensack Meridian Health
Merck Sharp & Dohme LLC

Withdrawn

Pembrolizumab, Belantamab and Dexamethasone in Refractory Multiple Myeloma.

Multiple Myeloma, Refractory

United States
University of California, San Francisco

Terminated

Doxil® + Melphalan + Velcade (DMV) in Relapsed/Refractory Multiple Myeloma (DMV)

Multiple Myeloma | Patient Participation

United States
Eikon Therapeutics

Recruiting

A Phase 2 Study of EIK1001 in Combination With Pembrolizumab and Chemotherapy in Patients With Stage 4 Non-Small Cell Lung Cancer

NSCLC

United States
AstraZeneca

Recruiting

A Study to Investigate the Efficacy of Durvalumab Plus Tremelimumab in Combination With Chemotherapy Compared With Pembrolizumab in Combination With Chemotherapy in Metastatic Non-Small Cell Lung Cancer (NSCLC) Patients (TRITON)

Carcinoma, Non-Small-Cell Lung

United States
Hoffmann-La Roche

Recruiting

A Study of Tobemstomig Plus Platinum-Based Chemotherapy vs Pembrolizumab Plus Platinum-Based Chemotherapy in Participants With Previously Untreated Non-Small Cell Lung Cancer

Non-small Cell Lung Cancer

Korea, Republic of, United States, Canada, Turkey, Brazil, Spain, France, Germany, Australia, Italy, Belgium, Mexico
Zin W Myint
Merck Sharp & Dohme LLC

Recruiting

Pembro With Radiation With or Without Olaparib

Prostate Cancer

United States
ImmunoVaccine Technologies, Inc. (IMV Inc.)
Merck Sharp & Dohme LLC

Recruiting

DPX-Survivac and Pembrolizumab With and Without Intermittent Low-Dose Cyclophosphamide, in Subjects With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (VITALIZE)

Relapsed Diffuse Large B-cell Lymphoma | Refractory Diffuse Large B-cell Lymphoma

Australia, Spain, United States, France, Hungary, New Zealand, Poland, Serbia, Canada, Romania
Incyte Corporation
Merck Sharp & Dohme LLC

Active, not recruiting

Pembrolizumab (MK-3475) Plus Epacadostat vs Standard of Care in mRCC (KEYNOTE-679/ECHO-302)

Renal Cell Carcinoma (RCC)

Canada, France, United States, Spain, United Kingdom, Italy, Taiwan, Australia, Norway, Korea, Republic of, Germany, Russian Federation, Japan, Brazil, Turkey, Ukraine, Hungary, New Zealand, Chile, Ireland
Hackensack Meridian Health

Completed

Allogeneic Hematopoietic Stem Cell Transplantation for Multiple Myeloma (Flu-Mel-Vel)

Multiple Myeloma

United States
University of Leeds
Karyopharm Therapeutics Inc; Myeloma UK

Withdrawn

Pembrolizumab Cyclophosphamide and Lenalidomide for Patients With Relapsed Multiple Myeloma (MUKfourteen)

Myeloma Multiple

United Kingdom
Merck Sharp & Dohme LLC

Completed

Study of Epacadostat (INCB024360) Alone and In Combination With Pembrolizumab (MK-3475) With Chemotherapy and Pembrolizumab Without Chemotherapy in Participants With Advanced Solid Tumors (MK-3475-434)

Neoplasms | Carcinoma, Non-Small-Cell Lung
Vanderbilt-Ingram Cancer Center
Merck Sharp & Dohme LLC

Recruiting

Pembrolizumab After Radiation Therapy and Chemotherapy in Limited Stage Small Cell Lung Cancer

Limited Stage Lung Small Cell Carcinoma | Stage III Lung Cancer | Stage I Lung Cancer | Stage II Lung Cancer

United States
Merck Sharp & Dohme LLC

Active, not recruiting

Efficacy and Safety of Pembrolizumab (MK-3475) Plus Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus Enzalutamide Plus ADT in Participants With Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) (MK-3475-991/KEYNOTE-991)-China Extension

Metastatic Hormone-Sensitive Prostate Cancer

China
Trishula Therapeutics, Inc.

Completed

TTX-030 Single Agent and in Combination With Immunotherapy or Chemotherapy for Patients With Advanced Cancers

Lymphoma | Solid Tumor

United States
M.D. Anderson Cancer Center
Zentalis Pharmaceuticals

Withdrawn

Phase I Study of ZN-c3 and Bevacizumab ± Pembrolizumab in Metastatic CCNE1 Amplified and TP53 Mutant Solid Tumors

Breast Cancer | Pancreatic Cancer | Ovarian Cancer | Lung Cancer | Tumors

United States
H. Lee Moffitt Cancer Center and Research Institute
Millennium Pharmaceuticals, Inc.

Completed

Melphalan+Bortezomib as a Conditioning Regimen for Autologous and Allogeneic Stem Cell Transplants in Multiple Myeloma

Multiple Myeloma

United States
M.D. Anderson Cancer Center

Completed

Lenalidomide and High-Dose Melphalan

Stem Cell Transplantation | Myeloma

United States
Nantes University Hospital

Completed

Trial of Carfilzomib Plus Melphalan and Prednisone in Elderly Untreated Patients With Multiple Myeloma (CARMYSAP) (CARMYSAP)

Myeloma

France
Merck Sharp & Dohme LLC

Recruiting

Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)

Non-small Cell Lung Cancer (NSCLC)

China, Australia, United States, Turkey, Chile, Taiwan, Denmark, France, Spain, Argentina, Italy, Netherlands, Thailand, Korea, Republic of
Gilead Sciences
Alliance Foundation Trials, LLC.; NSABP Foundation Inc

Recruiting

Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/NSABP B-63) (ASCENT-05)

Triple Negative Breast Cancer

United States
Massachusetts General Hospital
Massachusetts Institute of Technology

Recruiting

PD-1 Antibody Therapy + Infliximab for Metastatic Melanoma

Metastatic Melanoma

United States
McGill University Health Centre/Research Institute...

Recruiting

Pembrolizumab as Neoadjuvant Therapy for Resectable Stage IA3 to IIA Non-Small Cell Lung Cancer (NSCLC)

Lung Cancer, Nonsmall Cell

Canada
Karyopharm Therapeutics Inc

Recruiting

Relative Bioavailability/Bioequivalence of Different Formulations of Selinexor, the Impact of Hepatic Impairment on Selinexor Pharmacokinetics, Tolerability and Antitumor Activity of Selinexor Combination Treatment (SPRINT)

Other Solid Tumors | Colorectal Cancer (CRC) | Non-Small Cell Lung Carcinoma (NSCLC)

Israel
Gilead Sciences
Merck Sharp & Dohme LLC

Active, not recruiting

Study of Sacituzumab Govitecan Combinations in First-line Treatment of Participants With Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC) (EVOKE-02)

Non-small Cell Lung Cancer

United States, Spain, Italy, France, Australia, Hong Kong, Korea, Republic of, Malaysia, Taiwan, Germany, United Kingdom, Canada
Merck Sharp & Dohme LLC

Active, not recruiting

Substudy 02A: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents in Participants With Programmed Cell-death 1 (PD-1) Refractory Melanoma (MK-3475-02A/KEYMAKER-U02)

Melanoma

United States, Australia, France, Israel, Italy, Switzerland
H. Lee Moffitt Cancer Center and Research Institute
Merck Sharp & Dohme LLC

Completed

Pembrolizumab and Vorinostat Combined With Temozolomide for Newly Diagnosed Glioblastoma

Glioblastoma | Brain Tumor | GBM

United States
Soonchunhyang University Hospital

Completed

Busulfan, Melphalan and Etoposide as Conditioning for Autologous Transplantation for Non-Hodgkin's Lymphoma (NHL) (BME)

Non-Hodgkin's Lymphoma

Korea, Republic of
Jonsson Comprehensive Cancer Center
National Cancer Institute (NCI); Merck Sharp & Dohme LLC; Oncovir, Inc.; Phase...

Recruiting

Pembrolizumab and a Vaccine (ATL-DC) for the Treatment of Surgically Accessible Recurrent Glioblastoma

Recurrent Glioblastoma

United States
University of Alabama at Birmingham

Not yet recruiting

DISCERN: Dual Versus Single ICB in PDL-1 Negative NSCLC

Non Small Cell Lung Cancer

United States
Dartmouth-Hitchcock Medical Center

Not yet recruiting

A Study of Tetrathiomolybdate (TM) Plus Capecitabine

Triple Negative Breast Cancer | Residual Disease
Mirati Therapeutics Inc.

Recruiting

Combination Therapies With Adagrasib in Patients With Advanced NSCLC With KRAS G12C Mutation (202200050434)

Metastatic Lung Cancer | Advanced NSCLC

United States, Spain, Greece, Hungary, France, Italy, Poland
Marina Garassino

Recruiting

Metformin Plus/Minus Fasting Mimicking Diet to Target the Metabolic Vulnerabilities of LKB1-inactive Lung Adenocarcinoma (FAME)

Advanced LKB1-inactive Lung Adenocarcinoma

Italy
Arcus Biosciences, Inc.
Gilead Sciences

Active, not recruiting

Study Comparing the Combination Domvanalimab and Zimberelimab With Pembrolizumab in Untreated Locally Advanced or Metastatic PD-L1-High Non-Small Cell Lung Cancer (ARC-10)

Lung Cancer | Non Small Cell Lung Cancer | Squamous Non Small Cell Lung Cancer | Nonsquamous Non Small Cell Lung Cancer

Philippines, Thailand, France, Korea, Republic of, Hong Kong, United States, Turkey, Malaysia, Taiwan, Brazil, Serbia, Greece, Slovakia, Peru, South Africa, Mexico, Vietnam, Bangladesh
Merck Sharp & Dohme LLC

Active, not recruiting

Study of Olaparib Plus Pembrolizumab Versus Chemotherapy Plus Pembrolizumab After Induction With First-Line Chemotherapy Plus Pembrolizumab in Triple Negative Breast Cancer (TNBC) (MK-7339-009/KEYLYNK-009)

Triple Negative Breast Neoplasms

Colombia, United States, Canada, Chile, France, Germany, Hungary, Ireland, Japan, Korea, Republic of, Poland, Spain, Taiwan, Ukraine, United Kingdom
Merck Sharp & Dohme LLC

Active, not recruiting

Efficacy and Safety of Pembrolizumab (MK-3475) With Platinum Doublet Chemotherapy as Neoadjuvant/Adjuvant Therapy for Participants With Resectable Stage II, IIIA, and Resectable IIIB (T3-4N2) Non-small Cell Lung Cancer (MK-3475-671/KEYNOTE-671)

Non-small Cell Lung Cancer

United States, Argentina, Australia, Belgium, Brazil, Canada, China, Estonia, France, Germany, Ireland, Italy, Japan, Korea, Republic of, Latvia, Lithuania, Malaysia, Poland, Romania, Russian Federation, South Africa, Spain, Taiwan, U... and more
Novartis Pharmaceuticals

Withdrawn

Phase II Study Evaluating the Efficacy and Safety of Ociperlimab in Combination With Tislelizumab and Chemotherapy as First-line Treatment for Participants With Advanced Triple Negative Breast Cancer (AdvanTIG-211)

Triple Negative Breast Cancer
Okayama University
Merck Sharp & Dohme LLC

Recruiting

Novel Neoadjuvant and Adjuvant Strategy for Germline BRCA 1/2 Mutated Triple Negative Breast Cancer

Breast Cancer | Breast Neoplasms | Triple Negative Breast Cancer | Triple Negative Breast Neoplasms | BRCA1 Mutation | BRCA2 Mutation | BRCA Mutation | BRCA-Associated Breast Carcinoma

Japan

Search clinical trials for: Pembrolizumab

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Egypt

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations